Selective sodium channel inhibitor

This page covers all Selective sodium channel inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Voltage-gated sodium channels (Nav).

Targets

Voltage-gated sodium channels (Nav)

Marketed (1)

• Suzetrigine (SUZ) · Vertex Pharmaceuticals Incorporated · Pain management / Neurology
  Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.

Phase 3 pipeline (1)

• DS-5565 · Daiichi Sankyo Co., Ltd. · Neurology / Pain Management
  DS-5565 is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.

Patent intelligence

• selective sodium channel inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates